Global North America CRISPR Technology Market Size, Share and Trends Analysis
North America CRISPR Technology market size was $3.1B in 2023, forecasted to hit $10.2B by 2032, growing at 14.2% CAGR.
$3.1B
$10.2B
14.2%
North America
Executive Summary
The North America CRISPR technology market was valued at approximately $3.1 billion in 2023 and is projected to reach $10.2 billion by 2032, expanding at a CAGR of 14.2%. Growth is driven by rising genetic disorder prevalence, pharmaceutical R&D investment, and expanding clinical trials. CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics lead the competitive landscape. North America commands over 42% of the global market share, supported by robust regulatory frameworks and venture capital funding.
Key Highlights
Market projected to grow from $3.1B to $10.2B by 2032 at 14.2% CAGR
North America holds 42% global share led by US with 38% worldwide
CRISPR kits and reagents segment dominates at 35% market share
Market Overview
Market Context
The CRISPR technology market is in a high-growth phase driven by therapeutic breakthroughs, expanding clinical trials, and increasing biotech investment. North America leads globally with advanced infrastructure and regulatory clarity. Casgevy's approval set a commercial precedent.
The CRISPR technology market is experiencing high growth fueled by therapeutic breakthroughs, expanding gene editing applications, and increasing biotech investments. North America dominates globally with advanced research infrastructure. Casgevy's FDA approval in 2023 marked a pivotal commercial milestone for the industry.
Market Stage
High growth
Adoption Level
Growing
Key Trends
Market Forecast & Data
Base Year (2023)
$3.1B
Forecast (2032)
$10.2B
CAGR (2024-2032)
14.2%
| Year | Market size ($ Billion) |
|---|---|
| 2023Base year | $3.10B |
| 2024 | $3.54B |
| 2025 | $4.04B |
| 2026 | $4.62B |
| 2027 | $5.27B |
| 2028 | $6.02B |
| 2029 | $6.88B |
| 2030 | $7.85B |
| 2031 | $8.97B |
| 2032 | $10.24B |
Sustained double-digit growth expected through 2032, propelled by expanding oncology pipelines, rare disease therapies, and agricultural applications. Delivery system innovations will unlock new therapeutic areas.
| Region | Market share | Growth rate | Largest market |
|---|---|---|---|
| North America | 42.0% | 15.1% | United States |
| Europe | 30.0% | 12.8% | Germany |
| Asia Pacific | 28.0% | 16.5% | China |
North America
#1Largest market: United States
Europe
#2Largest market: Germany
Market Dynamics
- Rising prevalence of genetic disorders worldwide
- Increasing pharmaceutical R&D spending on gene therapies
- Advancements in CRISPR delivery systems
Market Segmentation
| Segment | Share |
|---|---|
| Drug Discovery & DevelopmentTarget identification, validation, and preclinical model development. | 40.0% |
| Genetic Disease TreatmentTherapeutic applications for monogenic and complex genetic disorders. | 25.0% |
| Agriculture & FoodCrop improvement, disease resistance, and livestock gene editing. | 15.0% |
| Industrial BiotechnologyMicrobial engineering for biofuels, enzymes, and chemical production. | 12.0% |
| DiagnosticsCRISPR-based molecular diagnostics including SHERLOCK and DETECTR platforms. | 8.0% |
| Total | 100.0% |
| Segment | Share |
|---|---|
| CRISPR Kits & ReagentsIncludes Cas9 enzymes, gRNA kits, and reagents for research applications. | 35.0% |
| CRISPR Therapeutics PipelineIn vivo and ex vivo therapeutic candidates across clinical trial stages. | 28.0% |
| Delivery SystemsViral and non-viral delivery platforms for targeted gene editing. | 18.0% |
| Software & BioinformaticsComputational tools for gRNA design, off-target prediction, and data analysis. | 12.0% |
| ServicesContract gene editing, screening, and custom CRISPR service offerings. | 7.0% |
| Total | 100.0% |
By End User
- Pharmaceutical & Biotech Companies
- Academic & Research Institutes
- Contract Research Organizations
- Hospitals & Clinics
Regional Analysis
North America
Lead: United StatesDominant region driven by advanced research infrastructure, FDA approvals, and strong venture capital funding.
Europe
Lead: GermanyGrowing adoption supported by EU research grants and emerging therapeutic approvals.
Asia Pacific
Lead: ChinaFastest-growing region due to government investment and expanding biotech sector.
Country-Level Analysis
| Country | Share | Growth |
|---|---|---|
| United States | 38.0% | +14.8% |
| Germany | 12.0% | +12.1% |
| China | 15.0% | +17.3% |
Competitive Landscape
CRISPR Therapeutics AG
Switzerland
Pioneered first FDA-approved CRISPR therapy Casgevy; strong oncology and hemoglobinopathy pipeline.
Global leader in CRISPR-based therapeutics, co-developer of Casgevy, the first FDA-approved CRISPR therapy for sickle cell disease.
Editas Medicine, Inc.
United States
Leading in vivo and ex vivo gene editing with ophthalmology and oncology programs advancing in trials.
Clinical-stage genome editing company advancing in vivo and ex vivo CRISPR therapies with lead ophthalmology program EDIT101.
Thermo Fisher Scientific Inc.
United States
Dominant CRISPR reagents and tools supplier; launched FDA-grade Cas enzymes for clinical-grade applications.
Global leader in CRISPR reagents, kits, and enzymes serving research and clinical-grade gene editing applications.
Recent Developments
Expanded oncology pipeline with CTX112 IND filing targeting solid tumors
BRILLIANCE Phase 1/2 trial showed 79% vision improvement in EDIT-101 treated patients
Regulatory Landscape
Research Methodology
Primary research
- Expert interviews
- Surveys
Secondary research
- Industry reports
- Company financials
Validation: Triangulation method
Strategic Takeaways
High-growth opportunity with 14.2% CAGR; therapeutics segment offers highest upside
Invest in delivery systems and bioinformatics to capture emerging market segments
North America remains primary market but Asia Pacific offers fastest growth potential
Frequently Asked Questions
Related research
Reports in the same field, each with its base-year figure and the growth rate it is published at.
- BiotechnologyGlobal CRISPR Technology Market$2.7B · 14.5% CAGR
- BiotechnologyGlobal United States CRISPR Technology Market$4.2B · 17% CAGR
- BiotechnologyGlobal North America Genomics Market$5.0B · 12% CAGR
- BiotechnologyGlobal Asia Pacific CRISPR Technology Market$1.2B · 16.5% CAGR
- BiotechnologyNorth America Cell & Gene Therapy Manufacturing Market$1.2B · 16% CAGR
- BiotechnologyGlobal North America Gene Therapy Market$10.0B · 30% CAGR